GLP-1 Dosage for Weight Loss: A Dose-by-Dose Guide (2026)

GLP-1 dosage for weight loss is not a single number: each medication starts at a low introductory dose and is raised in fixed steps over several months until it reaches a maintenance dose. Semaglutide (Wegovy) climbs from 0.25 mg to 2.4 mg once weekly, tirzepatide (Zepbound) from 2.5 mg to a maximum of 15 mg once weekly, and liraglutide (Saxenda) from 0.6 mg to 3.0 mg once daily. The starting doses are deliberately too low to do much on the scale. Their job is to let the body adapt so the higher, effective doses become tolerable. This guide gives the standard dose ladder for each main agent, explains why the slow climb matters, and covers maintenance dosing and what happens when a step is not tolerated.

One thing to fix up front: this is an educational GLP-1 dosage guide, not personal medical advice. The numbers below are the standard manufacturer labelling. The actual dose any individual takes, and the pace of every increase, is set and adjusted by a prescriber based on response, tolerability, and the specific product. For the full science behind these drugs, the complete guide to GLP-1 medications provides the background this builds on.

Why GLP-1 dosage for weight loss is built around titration

The single most important fact about GLP-1 dosing is that you do not start on the dose that does the work. Treatment opens low and rises in steps, a process called titration. This is true for every drug in the class, and the reason is the same across all of them.

GLP-1 receptor agonists work in large part by slowing the rate at which the stomach empties, which makes meals produce a longer-lasting sense of fullness. That slowed gastric emptying is also the direct source of the most common side effects: nausea, vomiting, and a sense of early or excessive fullness, especially in the first weeks at any given dose. As Daniel Drucker's 2018 synthesis in Cell Metabolism sets out, the appetite effect and the gastrointestinal side effects come from the same mechanism. The nausea is, in effect, the appetite machinery overshooting before the body has adjusted.

Starting at the full dose would expose the gut to that effect all at once, and for most people the side effects would be severe enough to make them stop. Titration sidesteps this by keeping adaptation ahead of the dose: each step is held long enough for the digestive system to habituate before the next increase. Skipping or rushing the climb is one of the most common reasons people experience side effects bad enough to quit. The slowness is the feature, not a flaw. The symptom-by-symptom arc over these weeks is laid out in the GLP-1 side effects timeline.

GLP-1 dose ladders at a glance: the per-drug titration table

The three medications approved for weight management each have their own dose ladder, but the shape is identical: a non-therapeutic starter dose, a series of monthly increases, and a maintenance dose held long-term. The table below gives the standard label schedule for each.

Medication (brand)	Frequency	Starting dose	Escalation steps	Maintenance / max dose	Typical time to reach it
Semaglutide (Wegovy)	Once weekly	0.25 mg	0.5, 1.0, 1.7 mg	2.4 mg	About 16 to 17 weeks
Tirzepatide (Zepbound)	Once weekly	2.5 mg	5, 7.5, 10, 12.5 mg	10 mg or 15 mg	About 20 to 24 weeks
Liraglutide (Saxenda)	Once daily	0.6 mg	1.2, 1.8, 2.4 mg	3.0 mg	About 4 to 5 weeks

Each step is normally held for about four weeks before the next increase (one week per step for daily liraglutide). The intervals are minimums, not deadlines. A prescriber may extend any step, or step back down, if side effects need more time to settle. The sections below walk through each agent in turn.

Semaglutide (Wegovy): 0.25 mg to 2.4 mg once weekly

Semaglutide for weight management is sold as Wegovy and titrates across five dose levels, each held for four weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and the full 2.4 mg maintenance dose reached at around week 17. In the STEP 1 trial led by John Wilding and published in the New England Journal of Medicine in 2021, this stepwise escalation to 2.4 mg produced a mean weight loss of about 14.9% over 68 weeks.

The 0.25 mg starter is explicitly a non-therapeutic dose, too low to produce the trial weight loss and not meant to. A common point of confusion is that the same molecule is sold as Ozempic for type 2 diabetes, where the ceiling is 2.0 mg weekly rather than Wegovy's 2.4 mg. The week-by-week detail, the Ozempic difference, and the oral Rybelsus form are covered in full in the dedicated semaglutide dosing schedule. The broader mechanism sits in how semaglutide works for weight loss.

Tirzepatide (Zepbound): 2.5 mg to 15 mg once weekly

Tirzepatide is a dual GLP-1 and GIP receptor agonist sold as Zepbound for weight management. Its ladder has more rungs: a 2.5 mg starter for four weeks, then increases to 5 mg, 7.5 mg, 10 mg, and 12.5 mg, up to a maximum of 15 mg, with each step held for at least four weeks. Because there are more steps, reaching the top dose typically takes around five to six months. Unlike semaglutide, tirzepatide has more than one approved maintenance dose: 5 mg, 10 mg, and 15 mg are all recognised maintenance options, so a prescriber may settle a person at 5 mg or 10 mg rather than pushing to 15 mg.

In Ania Jastreboff's SURMOUNT-1 trial, published in the NEJM in 2022, mean weight loss was about 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on the 15 mg dose over 72 weeks. The dose-response is real: higher doses produced more weight loss on average, which is part of why the ladder runs as high as it does. How the dual mechanism produces that effect is explained in how tirzepatide works.

Liraglutide (Saxenda): 0.6 mg to 3.0 mg once daily

Liraglutide is an earlier, shorter-acting GLP-1 agonist that requires a daily injection rather than a weekly one. Sold as Saxenda for weight management, it starts at 0.6 mg daily and increases by 0.6 mg each week: 1.2 mg, 1.8 mg, 2.4 mg, and the 3.0 mg maintenance dose, reached after about four weeks. Because the steps are weekly rather than monthly, the climb to the full dose is faster than the weekly agents, though the daily injection is a practical burden the once-weekly drugs avoid.

Liraglutide produces more modest weight loss than semaglutide or tirzepatide and has largely been superseded by the weekly agents for new prescriptions, but it remains in use and its dose ladder follows the same start-low logic. The same titration principle applies regardless of which agent: introduce the drug gently, raise it in steps, and let tolerance build.

What "maintenance dose" means in a GLP-1 dosage plan

The top of each ladder is the maintenance dose, the dose held long-term once titration is complete. It is worth being clear that the maximum dose and the right maintenance dose are not always the same thing. The full dose is a target, not an obligation.

A meaningful number of people achieve good results and better tolerability below the maximum, and a prescriber may decide the right long-term dose is 1.0 mg or 1.7 mg of semaglutide, or 5 mg or 10 mg of tirzepatide, rather than the ceiling. The question of what dose to settle on for the long term, and why some people stay below the maximum, is the subject of the GLP-1 maintenance dose. There is also growing interest in deliberately low maintenance dosing, discussed in the micro-dosing GLP-1 trend, though the evidence there is thinner and the practice is not part of standard labelling.

Maintenance is also where the chronic-disease nature of these drugs shows. The trials are consistent: when the medication is stopped, much of the lost weight returns, because the underlying appetite biology is unchanged. The STEP 4 trial, led by Domenica Rubino and published in JAMA in 2021, found that people switched to placebo after titration regained roughly two-thirds of their lost weight over the following year, while those who continued kept losing. For most people, the maintenance dose is not a finish line but an ongoing treatment, much as one would expect for a chronic condition like high blood pressure.

What to do if a GLP-1 dose isn't tolerated

Not everyone moves smoothly up the ladder, and every one of these schedules anticipates that. If side effects at a particular step are difficult, persistent nausea, vomiting, or fullness that interferes with eating adequately, the standard response is not to push through. The labels provide for delaying the next increase, holding at the current dose longer, or temporarily stepping back down to the previous dose until symptoms settle before trying to advance again. None of these is a failure of treatment. They are the schedule working as designed.

Several practical measures help side effects settle enough to stay on the ladder, and they follow directly from the slowed-gastric-emptying mechanism. Smaller meals eaten more slowly ask less of a stomach that is already emptying slowly. Reducing high-fat foods helps, since fat empties especially slowly. Staying well hydrated addresses both nausea and the constipation that titration can bring. These approaches are detailed in managing nausea on GLP-1. What the first weeks actually feel like, including why early progress on the scale is often slow by design, is covered in the first month on GLP-1.

Why a higher GLP-1 dose isn't automatically the right one

The dose-response in the trials can make it tempting to chase the maximum, but more is not automatically better for any given person. The right dose balances weight effect against tolerability, and the two do not always favour the ceiling.

Early doses feel underwhelming on the scale precisely because they are below the therapeutic level. People sometimes worry the medication "isn't working" during titration when, in most cases, it is working exactly as designed: building tolerance so the doses that move weight can be reached and sustained. Judging the drug by the starter dose is judging it before it has been given its effective dose. At the other end, a person who tolerates a mid-ladder dose well and is meeting their goals may have no reason to climb higher, since each step up also raises the chance of side effects. The dose-finding is individualised, which is the whole reason these are prescription medicines evaluated by a clinician rather than products taken to a self-set target.

How the agents compare on dosing, briefly

Across the class, the dosing differences come down to frequency, the number of steps, and the ceiling. Liraglutide is daily and reaches its 3.0 mg maintenance dose in about a month. Semaglutide is weekly and takes about four months to reach 2.4 mg. Tirzepatide is weekly with the longest ladder, up to five or six months to reach 15 mg, but also the highest average weight loss in trials and more than one recognised maintenance dose. None of this makes one drug the universally correct choice. The selection depends on indication, tolerability, access, cost, and clinical judgement, and is a decision for a prescriber rather than a comparison table. The deeper comparison of the molecules themselves lives in the GLP-1 science pillar.

Key takeaways

• GLP-1 dosage for weight loss always starts low and rises in steps. The starter doses are deliberately below the level that drives weight loss.
• Semaglutide (Wegovy) goes 0.25 mg to 2.4 mg weekly; tirzepatide (Zepbound) 2.5 mg to 15 mg weekly; liraglutide (Saxenda) 0.6 mg to 3.0 mg daily.
• Titration exists because the appetite effect and the gastrointestinal side effects share one mechanism: slowed gastric emptying. The slow climb keeps the gut adapting ahead of the dose.
• The maximum dose and the right maintenance dose are not always the same. Many people do well below the ceiling.
• If a step is not tolerated, the standard response is to hold, delay, or step back down, not to push through.
• Dosing is individualised by a prescriber. The numbers here are standard labelling for education, not a self-directed plan.

Want clear, unbiased GLP-1 guidance, without the sales pitch? Modern Weight Science is independent and evidence-based. Subscribe to our free weekly newsletter for plain-English updates on the science, dosing, and access, with no spam and no product pitches.